Dawnrays Pharma has made great efforts to develop system specific medicines, and the cardiovascular system is its main research direction as well as the medicine field it had built-up advantages.
Dawnrays Pharma has successfully developed brand anti-hypertensive drugs in "An" series of medicines. The drugs include Amlozen™, An Meiping, An Neixi, Armotan™ and An Liya.
Dawnrays Pharma had participated in the integrated medical project (Chinese Hypertension Intervention Efficacy Study, CHIEF Study) for the prevention and treatment of hypertension in 2007, the largest of its kind in China at the time, as the exclusive research and cooperation partner and designated supplier for drugs used in the research.

苏公网安备 32050602010200号